Latest stories on KROS
Keros Therapeutics, Inc. (KROS) files 8-K
SEC 8-K50 · neutralgeneral
KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026? - qz.com
Quartz58 · neutralgeneral
Keros Therapeutics’ TROPOS Trial Termination: What It Means for KROS Investors
TipRanks28 · bearishgeneral
Keros Therapeutics Appoints Anne Prener to Board
TipRanks55 · neutralgeneral
Keros Therapeutics, Inc. (KROS) files 8-K
SEC 8-K50 · neutralgeneral
Keros Therapeutics Appoints Anne Prener to its Board of Directors | KROS Stock News
StockTitan56 · neutralgeneral
Keros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha56 · neutralgeneral
Keros Therapeutics Stockholders Approve Directors and Governance Matters
TipRanks50 · neutralgeneral
Keros Therapeutics CEO to Present at Goldman Sachs Conference
TipRanks55 · neutralgeneral
Keros Therapeutics GAAP EPS of -$1.21 misses by $0.19, revenue of $0.37M misses by $1.32M
Seeking Alpha34 · bearishearnings